Aloracetam

Aloracetam
Systematic (IUPAC) name
N-[2-(3-Formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide
Clinical data
Legal status
Legal status
  • US: Not FDA approved; Unscheduled
Identifiers
CAS Number 119610-26-3 YesY
ATC code none
PubChem CID 178134
ChemSpider 155069 YesY
UNII U0RKZ75D0T YesY
ChEMBL CHEMBL2104637
Chemical data
Formula C11H16N2O2
Molar mass 208.257 g/mol
  (verify)

Aloracetam (INN) is a drug described as a nootropic which is closely related to, but technically not of (as it lacks a pyrrolidone ring), the racetam family of compounds.[1][2][3] It was studied by Aventis for the treatment of Alzheimer's disease,[4] but was never marketed.

See also

References

  1. "The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" (PDF). World Health Organization. 2011. Retrieved 22 May 2015.
  2. Charles F. George (7 July 1998). Drug Therapy in Old Age. Wiley. ISBN 978-0-471-94149-1.
  3. C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 615–. ISBN 978-0-412-46630-4.
  4. Fischer F, Matthisson M, Herrling P. List of Drugs in Development for Neurodegenerative Diseases. Neurodegenerative Diseases 2004;1:50–70.



This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.